CA2598207A1 - Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation - Google Patents

Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation Download PDF

Info

Publication number: CA2598207A1
Authority: CA; Canada
Prior art keywords: group; hydroxy; groups; general formula; compounds
Prior art date: 2005-04-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002598207A

Other languages

English (en)

Inventor

Norbert Schmees

Markus Berger

Hartmut Rehwinkel

Heike Schaecke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Schering AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-14

Filing date

2006-04-13

Publication date

2006-10-19

2006-04-13 Application filed by Schering AG filed Critical Schering AG

2006-10-19 Publication of CA2598207A1 publication Critical patent/CA2598207A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 47
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
230000001741 anti-phlogistic effect Effects 0.000 title abstract 2
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 149
-1 sulfonimine groups Chemical group 0.000 claims description 114
239000000203 mixture Substances 0.000 claims description 73
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
125000005843 halogen group Chemical group 0.000 claims description 22
125000001424 substituent group Chemical group 0.000 claims description 20
125000004093 cyano group Chemical group *C#N 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 15
125000001072 heteroaryl group Chemical group 0.000 claims description 14
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 13
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 13
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 12
125000004430 oxygen atom Chemical group O* 0.000 claims description 11
125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 9
230000004054 inflammatory process Effects 0.000 claims description 9
125000004434 sulfur atom Chemical group 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000001153 fluoro group Chemical group F* 0.000 claims description 6
125000000623 heterocyclic group Chemical group 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
125000003107 substituted aryl group Chemical group 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
125000002619 bicyclic group Chemical group 0.000 claims description 5
125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims description 5
125000000468 ketone group Chemical group 0.000 claims description 5
125000002950 monocyclic group Chemical group 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 4
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
150000002466 imines Chemical class 0.000 claims description 4
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 4
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 4
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
125000005633 phthalidyl group Chemical group 0.000 claims description 4
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
229940127557 pharmaceutical product Drugs 0.000 claims description 2
125000000565 sulfonamide group Chemical group 0.000 claims description 2
125000000542 sulfonic acid group Chemical group 0.000 claims description 2
125000004962 sulfoxyl group Chemical group 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 4
150000001420 substituted heterocyclic compounds Chemical class 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
239000000243 solution Substances 0.000 description 67
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
230000008569 process Effects 0.000 description 40
238000002360 preparation method Methods 0.000 description 37
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 34
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
229910052938 sodium sulfate Inorganic materials 0.000 description 29
235000011152 sodium sulphate Nutrition 0.000 description 29
101150041968 CDC13 gene Proteins 0.000 description 24
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
239000012267 brine Substances 0.000 description 24
239000012074 organic phase Substances 0.000 description 24
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
239000000741 silica gel Substances 0.000 description 23
229910002027 silica gel Inorganic materials 0.000 description 23
238000005160 1H NMR spectroscopy Methods 0.000 description 22
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
238000004587 chromatography analysis Methods 0.000 description 20
230000002757 inflammatory effect Effects 0.000 description 19
238000003786 synthesis reaction Methods 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
208000010668 atopic eczema Diseases 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
230000000172 allergic effect Effects 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
230000002062 proliferating effect Effects 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
239000003921 oil Substances 0.000 description 14
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 12
229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
235000017557 sodium bicarbonate Nutrition 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 10
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
150000002009 diols Chemical class 0.000 description 9
102000003676 Glucocorticoid Receptors Human genes 0.000 description 8
108090000079 Glucocorticoid Receptors Proteins 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000006260 foam Substances 0.000 description 8
150000001299 aldehydes Chemical class 0.000 description 7
230000003110 anti-inflammatory effect Effects 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000005406 washing Methods 0.000 description 7
BYQIWIJRXKIUAA-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropanal Chemical compound C1=CC=C2C(CC(O)(C=O)C(F)(F)F)CCOC2=C1 BYQIWIJRXKIUAA-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000003862 glucocorticoid Substances 0.000 description 6
239000012280 lithium aluminium hydride Substances 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
208000019693 Lung disease Diseases 0.000 description 5
102000016540 Tyrosine aminotransferases Human genes 0.000 description 5
108010042606 Tyrosine transaminase Proteins 0.000 description 5
238000001035 drying Methods 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
GOWIMSLPMYWHDU-UHFFFAOYSA-N 3-(3,4-dihydro-2h-chromen-4-yl)-1,1,1-trifluoropropan-2-ol Chemical compound C1=CC=C2C(CC(O)C(F)(F)F)CCOC2=C1 GOWIMSLPMYWHDU-UHFFFAOYSA-N 0.000 description 4
ROMVUMDSJABECR-UHFFFAOYSA-N 3-(3,4-dihydro-2h-chromen-4-yl)-1,1,1-trifluoropropan-2-one Chemical compound C1=CC=C2C(CC(=O)C(F)(F)F)CCOC2=C1 ROMVUMDSJABECR-UHFFFAOYSA-N 0.000 description 4
208000026872 Addison Disease Diseases 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 4
102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 4
102000003998 progesterone receptors Human genes 0.000 description 4
108090000468 progesterone receptors Proteins 0.000 description 4
229940037128 systemic glucocorticoids Drugs 0.000 description 4
LMRIOHSOFVMYMH-UHFFFAOYSA-N 1,1,1-trifluoro-2-[(4-methyl-2,3-dihydrochromen-4-yl)methyl]but-3-en-2-ol Chemical compound C1=CC=C2C(C)(CC(O)(C=C)C(F)(F)F)CCOC2=C1 LMRIOHSOFVMYMH-UHFFFAOYSA-N 0.000 description 3
QWASRIJPLWDQCC-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-yl)ethanol Chemical compound C1=CC=C2C(CCO)CCOC2=C1 QWASRIJPLWDQCC-UHFFFAOYSA-N 0.000 description 3
BFQGXXNOHZAYSB-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-ylmethyl)-1,1,1-trifluorobut-3-en-2-ol Chemical compound C1=CC=C2C(CC(O)(C=C)C(F)(F)F)CCOC2=C1 BFQGXXNOHZAYSB-UHFFFAOYSA-N 0.000 description 3
VVHMFTLLQKJSRT-UHFFFAOYSA-N 2-(3,4-dihydro-2h-thiochromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropanal Chemical compound C1=CC=C2C(CC(O)(C=O)C(F)(F)F)CCSC2=C1 VVHMFTLLQKJSRT-UHFFFAOYSA-N 0.000 description 3
VRJSBXXYYVKFJP-UHFFFAOYSA-N 2-(3,4-dihydro-2h-thiochromen-4-ylmethyl)-3,3,3-trifluoropropane-1,2-diol Chemical compound C1=CC=C2C(CC(O)(CO)C(F)(F)F)CCSC2=C1 VRJSBXXYYVKFJP-UHFFFAOYSA-N 0.000 description 3
DTBHAPLDDIUREV-UHFFFAOYSA-N 2-(4-methyl-2,3-dihydrochromen-4-yl)acetaldehyde Chemical compound C1=CC=C2C(C)(CC=O)CCOC2=C1 DTBHAPLDDIUREV-UHFFFAOYSA-N 0.000 description 3
ZIHWXNVRIAJESR-UHFFFAOYSA-N 3,3,3-trifluoro-2-(2h-thiochromen-4-ylmethyl)propane-1,2-diol Chemical compound C1=CC=C2C(CC(O)(CO)C(F)(F)F)=CCSC2=C1 ZIHWXNVRIAJESR-UHFFFAOYSA-N 0.000 description 3
DLRKJIFFNNMDQM-UHFFFAOYSA-N 4-methylidene-2,3-dihydrothiochromene Chemical compound C1=CC=C2C(=C)CCSC2=C1 DLRKJIFFNNMDQM-UHFFFAOYSA-N 0.000 description 3
UXDSORPRXPHDBA-UHFFFAOYSA-N 5-[[2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropylidene]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N=CC(C(F)(F)F)(O)CC1C2=CC=CC=C2OCC1 UXDSORPRXPHDBA-UHFFFAOYSA-N 0.000 description 3
OSMXJIZJSGKKSG-UHFFFAOYSA-N 5-[[2-(3,4-dihydro-2h-thiochromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropylidene]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N=CC(C(F)(F)F)(O)CC1C2=CC=CC=C2SCC1 OSMXJIZJSGKKSG-UHFFFAOYSA-N 0.000 description 3
UUALSKMKENKFIY-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-hydroxy-2-[(4-methyl-2,3-dihydrochromen-4-yl)methyl]propyl]amino]-1h-quinolin-2-one Chemical compound C1COC2=CC=CC=C2C1(C)CC(O)(C(F)(F)F)CNC1=CC=CC2=C1C=CC(=O)N2 UUALSKMKENKFIY-UHFFFAOYSA-N 0.000 description 3
DANDEJPAZFBPAS-UHFFFAOYSA-N 5-amino-1h-quinolin-2-one Chemical compound OC1=CC=C2C(N)=CC=CC2=N1 DANDEJPAZFBPAS-UHFFFAOYSA-N 0.000 description 3
206010002199 Anaphylactic shock Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000012659 Joint disease Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
208000025747 Rheumatic disease Diseases 0.000 description 3
206010039085 Rhinitis allergic Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000004414 alkyl thio group Chemical group 0.000 description 3
125000001118 alkylidene group Chemical group 0.000 description 3
201000010105 allergic rhinitis Diseases 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
229940117173 croton oil Drugs 0.000 description 3
GUVNANFTYBZTQP-UHFFFAOYSA-N ethyl 2-(2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropanoate Chemical compound C1=CC=C2C(CC(O)(C(=O)OCC)C(F)(F)F)=CCOC2=C1 GUVNANFTYBZTQP-UHFFFAOYSA-N 0.000 description 3
AXCPCVBRKSIWLG-UHFFFAOYSA-N ethyl 3,3,3-trifluoro-2-hydroxy-2-(2h-thiochromen-4-ylmethyl)propanoate Chemical compound C1=CC=C2C(CC(O)(C(=O)OCC)C(F)(F)F)=CCSC2=C1 AXCPCVBRKSIWLG-UHFFFAOYSA-N 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 3
125000002524 organometallic group Chemical group 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000035939 shock Effects 0.000 description 3
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
ZHVXNRPOHAAVMX-UHFFFAOYSA-N 1,1,1-trifluoro-3-(4-methyl-2,3-dihydrochromen-4-yl)propan-2-ol Chemical compound C1=CC=C2C(C)(CC(O)C(F)(F)F)CCOC2=C1 ZHVXNRPOHAAVMX-UHFFFAOYSA-N 0.000 description 2
KRGMIRFXDTWENQ-UHFFFAOYSA-N 1,1,1-trifluoro-3-(4-methyl-2,3-dihydrochromen-4-yl)propan-2-one Chemical compound C1=CC=C2C(C)(CC(=O)C(F)(F)F)CCOC2=C1 KRGMIRFXDTWENQ-UHFFFAOYSA-N 0.000 description 2
ZLKCQIBIETUFNU-UHFFFAOYSA-N 2-(2h-chromen-4-ylmethyl)-1,1,1-trifluoro-3-[(2-methylquinolin-5-yl)amino]propan-2-ol Chemical compound C1=CC=C2C(CC(O)(CNC=3C4=CC=C(N=C4C=CC=3)C)C(F)(F)F)=CCOC2=C1 ZLKCQIBIETUFNU-UHFFFAOYSA-N 0.000 description 2
GPOYJWPCEVDECS-UHFFFAOYSA-N 2-(2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropanal Chemical compound C1=CC=C2C(CC(O)(C=O)C(F)(F)F)=CCOC2=C1 GPOYJWPCEVDECS-UHFFFAOYSA-N 0.000 description 2
VAFAQRPMIWBARO-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-yl)acetaldehyde Chemical compound C1=CC=C2C(CC=O)CCOC2=C1 VAFAQRPMIWBARO-UHFFFAOYSA-N 0.000 description 2
BESDTRCKDNIKDM-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-trimethylsilyloxypropanenitrile Chemical compound C1=CC=C2C(CC(O[Si](C)(C)C)(C#N)C(F)(F)F)CCOC2=C1 BESDTRCKDNIKDM-UHFFFAOYSA-N 0.000 description 2
XLQHGLRAWWTASW-UHFFFAOYSA-N 2-(4-methyl-2,3-dihydrochromen-4-yl)ethanol Chemical compound C1=CC=C2C(C)(CCO)CCOC2=C1 XLQHGLRAWWTASW-UHFFFAOYSA-N 0.000 description 2
KGNWOIOTHSSWGW-UHFFFAOYSA-N 4-methylidene-2,3-dihydrochromene Chemical compound C1=CC=C2C(=C)CCOC2=C1 KGNWOIOTHSSWGW-UHFFFAOYSA-N 0.000 description 2
WCZZYLSUXFSAEW-UHFFFAOYSA-N 5-[[2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropylidene]amino]-2h-phthalazin-1-one Chemical compound C1=NNC(=O)C2=C1C(N=CC(CC1C3=CC=CC=C3OCC1)(O)C(F)(F)F)=CC=C2 WCZZYLSUXFSAEW-UHFFFAOYSA-N 0.000 description 2
GGYIYFZUMZZNFO-UHFFFAOYSA-N 5-[[2-(3,4-dihydro-2h-thiochromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino]-1h-quinolin-2-one Chemical compound C1CSC2=CC=CC=C2C1CC(C(F)(F)F)(O)CNC1=CC=CC2=C1C=CC(=O)N2 GGYIYFZUMZZNFO-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
102100032187 Androgen receptor Human genes 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229940126083 M3 antagonist Drugs 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
150000001204 N-oxides Chemical class 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
108010080146 androgen receptors Proteins 0.000 description 2
125000005427 anthranyl group Chemical group 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
208000006752 brain edema Diseases 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
239000012043 crude product Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
238000003810 ethyl acetate extraction Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000000414 obstructive effect Effects 0.000 description 2
229960002657 orciprenaline Drugs 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
208000023087 secondary adrenal insufficiency Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
235000019345 sodium thiosulphate Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
238000010792 warming Methods 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
PZWZSPSMSGAFJY-UHFFFAOYSA-N 1,1,1-trifluoro-2-[(2-methylquinolin-5-yl)iminomethyl]-3-(1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C1CCC2=CC=CC=C2C1CC(O)(C(F)(F)F)C=NC1=CC=CC2=NC(C)=CC=C21 PZWZSPSMSGAFJY-UHFFFAOYSA-N 0.000 description 1
IFZLLSOAVSSXKU-UHFFFAOYSA-N 1,1,1-trifluoro-2-[(2-methylquinolin-5-yl)iminomethyl]-3-(2-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound CC1=CC=C2C(N=CC(O)(CC3C4=CC=CC=C4CCC3C)C(F)(F)F)=CC=CC2=N1 IFZLLSOAVSSXKU-UHFFFAOYSA-N 0.000 description 1
FWWJFNYSBIVHDJ-UHFFFAOYSA-N 1,1,1-trifluoro-2-[(2-methylquinolin-5-yl)iminomethyl]-3-(4-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C12=CC=CC=C2C(C)CCC1CC(O)(C(F)(F)F)C=NC1=CC=CC2=NC(C)=CC=C12 FWWJFNYSBIVHDJ-UHFFFAOYSA-N 0.000 description 1
VAWDIQMUHTVDEN-UHFFFAOYSA-N 1,1,1-trifluoro-2-[(8-fluoro-2-methylquinazolin-5-yl)iminomethyl]-3-(1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C1CCC2=CC=CC=C2C1CC(O)(C(F)(F)F)C=NC1=CC=C(F)C2=NC(C)=NC=C21 VAWDIQMUHTVDEN-UHFFFAOYSA-N 0.000 description 1
WYLKQNJAQQNJHR-UHFFFAOYSA-N 1,1,1-trifluoro-2-[[(2-methylquinolin-5-yl)amino]methyl]-3-(1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C1CCC2=CC=CC=C2C1CC(O)(C(F)(F)F)CNC1=CC=CC2=NC(C)=CC=C21 WYLKQNJAQQNJHR-UHFFFAOYSA-N 0.000 description 1
HUFSLYJCJXJPTD-UHFFFAOYSA-N 1,1,1-trifluoro-2-[[(2-methylquinolin-5-yl)amino]methyl]-3-(2-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound CC1=CC=C2C(NCC(O)(CC3C4=CC=CC=C4CCC3C)C(F)(F)F)=CC=CC2=N1 HUFSLYJCJXJPTD-UHFFFAOYSA-N 0.000 description 1
MXYZDSHTNDMRFM-UHFFFAOYSA-N 1,1,1-trifluoro-2-[[(2-methylquinolin-5-yl)amino]methyl]-3-(4-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C12=CC=CC=C2C(C)CCC1CC(O)(C(F)(F)F)CNC1=CC=CC2=NC(C)=CC=C12 MXYZDSHTNDMRFM-UHFFFAOYSA-N 0.000 description 1
OJSYOSHOCWGZAM-UHFFFAOYSA-N 1,1,1-trifluoro-2-[[(8-fluoro-2-methylquinazolin-5-yl)amino]methyl]-3-(1,2,3,4-tetrahydronaphthalen-1-yl)propan-2-ol Chemical compound C1CCC2=CC=CC=C2C1CC(O)(C(F)(F)F)CNC1=CC=C(F)C2=NC(C)=NC=C21 OJSYOSHOCWGZAM-UHFFFAOYSA-N 0.000 description 1
125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 description 1
XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
CVQSWZMJOGOPAV-UHFFFAOYSA-N 2,3-dihydrothiochromen-4-one Chemical compound C1=CC=C2C(=O)CCSC2=C1 CVQSWZMJOGOPAV-UHFFFAOYSA-N 0.000 description 1
XDGMUKDZEXZCPT-UHFFFAOYSA-N 2-(2-methyl-3,4-dihydro-2h-chromen-4-yl)ethanol Chemical compound C1=CC=C2OC(C)CC(CCO)C2=C1 XDGMUKDZEXZCPT-UHFFFAOYSA-N 0.000 description 1
SNASXNGEBAFHEY-UHFFFAOYSA-N 2-(2h-chromen-4-ylmethyl)-1,1,1-trifluoro-3-(2-methylquinolin-5-yl)iminopropan-2-ol Chemical compound C1=CC=C2C(CC(O)(C=NC=3C4=CC=C(N=C4C=CC=3)C)C(F)(F)F)=CCOC2=C1 SNASXNGEBAFHEY-UHFFFAOYSA-N 0.000 description 1
UWTSGMCMNASRMG-UHFFFAOYSA-N 2-(3,4-dihydro-2H-thiochromen-4-yl)acetaldehyde 2-(4-ethyl-2,3-dihydrochromen-4-yl)acetaldehyde 2-(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)acetaldehyde 2-(4-methyl-2,3-dihydrothiochromen-4-yl)acetaldehyde 2-(4-propyl-2,3-dihydrochromen-4-yl)acetaldehyde Chemical compound C(CC)C1(CCOC2=CC=CC=C12)CC=O.C(C)C1(CCOC2=CC=CC=C12)CC=O.CC1(CCSC2=CC=CC=C12)CC=O.S1CCC(C2=CC=CC=C12)CC=O.FC=1C=C2CCCC(C2=CC1)CC=O UWTSGMCMNASRMG-UHFFFAOYSA-N 0.000 description 1
FGYFHHJGCMQVDV-UHFFFAOYSA-N 2-(3,4-dihydro-2H-thiochromen-4-yl)ethanol 2-(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)ethanol Chemical compound S1CCC(C2=CC=CC=C12)CCO.FC=1C=C2CCCC(C2=CC1)CCO FGYFHHJGCMQVDV-UHFFFAOYSA-N 0.000 description 1
XCUSNJDKVUTWDH-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-ylmethyl)-1,1,1-trifluoro-3-(8-fluoro-2-methylquinazolin-5-yl)iminopropan-2-ol Chemical compound C1COC2=CC=CC=C2C1CC(O)(C(F)(F)F)C=NC1=CC=C(F)C2=NC(C)=NC=C21 XCUSNJDKVUTWDH-UHFFFAOYSA-N 0.000 description 1
IWGFHSVANWUVBU-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-4-ylmethyl)-1,1,1-trifluoro-3-[(2-methylquinolin-5-yl)amino]propan-2-ol Chemical compound C1COC2=CC=CC=C2C1CC(O)(C(F)(F)F)CNC1=CC=CC2=NC(C)=CC=C21 IWGFHSVANWUVBU-UHFFFAOYSA-N 0.000 description 1
AZDWEZOQSXMNJE-UHFFFAOYSA-N 2-(4-ethyl-2,3-dihydrochromen-4-yl)ethanol 2-(4-methyl-2,3-dihydrothiochromen-4-yl)ethanol 2-(4-propyl-2,3-dihydrochromen-4-yl)ethanol Chemical compound C(CC)C1(CCOC2=CC=CC=C12)CCO.C(C)C1(CCOC2=CC=CC=C12)CCO.CC1(CCSC2=CC=CC=C12)CCO AZDWEZOQSXMNJE-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
QMDFJHAAWUGVKQ-UHFFFAOYSA-N 2h-thiopyran Chemical compound C1SC=CC=C1 QMDFJHAAWUGVKQ-UHFFFAOYSA-N 0.000 description 1
JMQVNXINWCCJRI-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxy-2-[(4-methyl-2,3-dihydrochromen-4-yl)methyl]propanal Chemical compound C1=CC=C2C(C)(CC(O)(C=O)C(F)(F)F)CCOC2=C1 JMQVNXINWCCJRI-UHFFFAOYSA-N 0.000 description 1
PTMRBVUJRQQRSR-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxy-2-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]propanal Chemical compound O=CC(O)(C(F)(F)F)CC1CCCC2=C1C=CC=C2OC PTMRBVUJRQQRSR-UHFFFAOYSA-N 0.000 description 1
GVDJEHMDNREMFA-UHFFFAOYSA-N 3,3,3-trifluoro-2-oxopropanoic acid Chemical compound OC(=O)C(=O)C(F)(F)F GVDJEHMDNREMFA-UHFFFAOYSA-N 0.000 description 1
BXDKXHGSGJYXDQ-UHFFFAOYSA-N 3,3,4,4,4-pentafluoro-1-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)butan-2-one Chemical compound FC(F)(F)C(F)(F)C(=O)CC1CCCC2=CC(OC)=CC=C21 BXDKXHGSGJYXDQ-UHFFFAOYSA-N 0.000 description 1
KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 1
MOLYCUGLEHVEBJ-UHFFFAOYSA-N 3-(4-ethyl-2,3-dihydrochromen-4-yl)-1,1,1-trifluoropropan-2-ol;1,1,1-trifluoro-3-(4-methyl-2,3-dihydrothiochromen-4-yl)propan-2-ol;1,1,1-trifluoro-3-(4-propyl-2,3-dihydrochromen-4-yl)propan-2-ol Chemical compound C1=CC=C2C(C)(CC(O)C(F)(F)F)CCSC2=C1.C1=CC=C2C(CC)(CC(O)C(F)(F)F)CCOC2=C1.C1=CC=C2C(CCC)(CC(O)C(F)(F)F)CCOC2=C1 MOLYCUGLEHVEBJ-UHFFFAOYSA-N 0.000 description 1
125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
125000004715 3-methylbutylthio group Chemical group CC(CCS*)C 0.000 description 1
MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
PNCFZNGNZYEAMJ-UHFFFAOYSA-N 4-[[2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropylidene]amino]-1,3-dihydroindol-2-one Chemical compound C1COC2=CC=CC=C2C1CC(O)(C(F)(F)F)C=NC1=CC=CC2=C1CC(=O)N2 PNCFZNGNZYEAMJ-UHFFFAOYSA-N 0.000 description 1
LGRQUXHYJBFGTM-UHFFFAOYSA-N 4H-imidazole Chemical compound C1C=NC=N1 LGRQUXHYJBFGTM-UHFFFAOYSA-N 0.000 description 1
MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
NILYRCYRBPDITI-UHFFFAOYSA-N 4H-pyrazole Chemical compound C1C=NN=C1 NILYRCYRBPDITI-UHFFFAOYSA-N 0.000 description 1
STBGWNRZMPCVTG-UHFFFAOYSA-N 4h-thiopyran Chemical compound C1C=CSC=C1 STBGWNRZMPCVTG-UHFFFAOYSA-N 0.000 description 1
XYCOXQKTEPQYMC-UHFFFAOYSA-N 5-[[2-(3,4-dihydro-2h-chromen-4-ylmethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino]-1h-quinolin-2-one Chemical compound C1COC2=CC=CC=C2C1CC(C(F)(F)F)(O)CNC1=CC=CC2=C1C=CC(=O)N2 XYCOXQKTEPQYMC-UHFFFAOYSA-N 0.000 description 1
TVDQTJMJASJQME-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-[(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]-2-hydroxypropyl]amino]-1h-quinolin-2-one Chemical compound C1CCC2=CC(F)=CC=C2C1CC(C(F)(F)F)(O)CNC1=CC=CC2=C1C=CC(=O)N2 TVDQTJMJASJQME-UHFFFAOYSA-N 0.000 description 1
HMXAADRFCCMSNC-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-[(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]-2-hydroxypropylidene]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N=CC(C(F)(F)F)(O)CC1C2=CC=C(F)C=C2CCC1 HMXAADRFCCMSNC-UHFFFAOYSA-N 0.000 description 1
LHTVYGPSJZOOBO-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)propylidene]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N=CC(C(F)(F)F)(O)CC1C2=CC=CC=C2CCC1 LHTVYGPSJZOOBO-UHFFFAOYSA-N 0.000 description 1
LTSMEYATOUZCSL-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-hydroxy-2-[(4-methyl-2,3-dihydrochromen-4-yl)methyl]propylidene]amino]-1h-quinolin-2-one Chemical compound C1COC2=CC=CC=C2C1(C)CC(O)(C(F)(F)F)C=NC1=CC=CC2=C1C=CC(=O)N2 LTSMEYATOUZCSL-UHFFFAOYSA-N 0.000 description 1
ONZOUGQUIKVWNB-UHFFFAOYSA-N 5-[[3,3,3-trifluoro-2-hydroxy-2-[(4-propyl-2,3-dihydrochromen-4-yl)methyl]propyl]amino]-1h-quinolin-2-one Chemical compound C1COC2=CC=CC=C2C1(CCC)CC(O)(C(F)(F)F)CNC1=CC=CC2=C1C=CC(=O)N2 ONZOUGQUIKVWNB-UHFFFAOYSA-N 0.000 description 1
NWNTTWQRGXBCGQ-UHFFFAOYSA-N 5-[[3,3,4,4,4-pentafluoro-2-hydroxy-2-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]butyl]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2NCC(O)(C(F)(F)C(F)(F)F)CC1C2=CC=C(OC)C=C2CCC1 NWNTTWQRGXBCGQ-UHFFFAOYSA-N 0.000 description 1
UIOOHXJSCKRWLX-UHFFFAOYSA-N 5-[[3,3,4,4,4-pentafluoro-2-hydroxy-2-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]butylidene]amino]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N=CC(O)(C(F)(F)C(F)(F)F)CC1C2=CC=C(OC)C=C2CCC1 UIOOHXJSCKRWLX-UHFFFAOYSA-N 0.000 description 1
PJCMURZRUATYFM-UHFFFAOYSA-N 5-amino-2h-phthalazin-1-one Chemical compound C1=NNC(=O)C2=C1C(N)=CC=C2 PJCMURZRUATYFM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
VKDCEZNDLSXFLR-UHFFFAOYSA-N 8-fluoro-2-methylquinazolin-5-amine Chemical compound NC1=CC=C(F)C2=NC(C)=NC=C21 VKDCEZNDLSXFLR-UHFFFAOYSA-N 0.000 description 1
PILPIITVELSUBH-UHFFFAOYSA-N 8-methylquinolin-5-amine Chemical compound C1=CN=C2C(C)=CC=C(N)C2=C1 PILPIITVELSUBH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000005676 Adrenogenital syndrome Diseases 0.000 description 1
238000006596 Alder-ene reaction Methods 0.000 description 1
206010057380 Allergic keratitis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
DGMQEVVEWKWTRK-UHFFFAOYSA-N C(CC)C1(CCOC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F.C(C)C1(CCOC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F.CC1(CCSC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F Chemical compound C(CC)C1(CCOC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F.C(C)C1(CCOC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F.CC1(CCSC2=CC=CC=C12)CC(C=C)(O)C(F)(F)F DGMQEVVEWKWTRK-UHFFFAOYSA-N 0.000 description 1
102000004500 CCR1 Receptors Human genes 0.000 description 1
108010017319 CCR1 Receptors Proteins 0.000 description 1
NDCIIBFSBYZCOF-UHFFFAOYSA-N COC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F.FC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F.CC1=CC=C2C(CCOC2=C1)CC(O)C(F)(F)F.CC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F Chemical compound COC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F.FC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F.CC1=CC=C2C(CCOC2=C1)CC(O)C(F)(F)F.CC=1C=C2C(CCOC2=CC1)CC(O)C(F)(F)F NDCIIBFSBYZCOF-UHFFFAOYSA-N 0.000 description 1
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
101100255205 Caenorhabditis elegans rsa-2 gene Proteins 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012441 Dermatitis bullous Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010013457 Dissociation Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
241001516614 Exema Species 0.000 description 1
208000028387 Felty syndrome Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
206010021750 Infantile Spasms Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
SOXVRNOIFBOXMB-UHFFFAOYSA-N O1CCC(C2=CC=CC=C12)CC(CNC1=C2CC(NC2=CC=C1)=O)(C(F)(F)F)O.O1CCC(C2=CC=CC=C12)CC(CNC1=C2C=NNC2=CC=C1)(C(F)(F)F)O Chemical compound O1CCC(C2=CC=CC=C12)CC(CNC1=C2CC(NC2=CC=C1)=O)(C(F)(F)F)O.O1CCC(C2=CC=CC=C12)CC(CNC1=C2C=NNC2=CC=C1)(C(F)(F)F)O SOXVRNOIFBOXMB-UHFFFAOYSA-N 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010052381 Primary adrenal insufficiency Diseases 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
208000016247 Soft tissue disease Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
201000002015 Thyroid Crisis Diseases 0.000 description 1
206010043786 Thyrotoxic crisis Diseases 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047112 Vasculitides Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
201000006791 West syndrome Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
208000002479 balanitis Diseases 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
229960000585 bitolterol mesylate Drugs 0.000 description 1
HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
208000010217 blepharitis Diseases 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
238000010410 dusting Methods 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
WOTDWJIODJIQEO-UHFFFAOYSA-N ethyl 2-(4-methyl-2,3-dihydrochromen-4-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)(C)CCOC2=C1 WOTDWJIODJIQEO-UHFFFAOYSA-N 0.000 description 1
KJHQVUNUOIEYSV-UHFFFAOYSA-N ethyl 3,3,3-trifluoro-2-oxopropanoate Chemical compound CCOC(=O)C(=O)C(F)(F)F KJHQVUNUOIEYSV-UHFFFAOYSA-N 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
150000004673 fluoride salts Chemical class 0.000 description 1
125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229960004078 indacaterol Drugs 0.000 description 1
QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
125000000493 isoindolonyl group Chemical group C1(N=C(C2=CC=CC=C12)*)=O 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
231100000832 liver cell necrosis Toxicity 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
150000002790 naphthalenes Chemical class 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
208000028931 non-acquired combined pituitary hormone deficiency Diseases 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
206010033072 otitis externa Diseases 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
229960001609 oxitropium bromide Drugs 0.000 description 1
LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
210000003695 paranasal sinus Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
125000005010 perfluoroalkyl group Chemical group 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
238000005375 photometry Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
229960004633 pirenzepine Drugs 0.000 description 1
RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
125000003808 silyl group Chemical class [H][Si]([H])([H])[*] 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
101150018444 sub2 gene Proteins 0.000 description 1
201000007497 subacute thyroiditis Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229950004351 telenzepine Drugs 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960000257 tiotropium bromide Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229910000314 transition metal oxide Inorganic materials 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
208000002003 vulvitis Diseases 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CA002598207A 2005-04-14 2006-04-13 Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation Abandoned CA2598207A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102005017301.2		2005-04-14
DE102005017301A DE102005017301A1 (de)	2005-04-14	2005-04-14	Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
PCT/EP2006/003780 WO2006108711A1 (fr)	2005-04-14	2006-04-13	Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation

Publications (1)

Publication Number	Publication Date
CA2598207A1 true CA2598207A1 (fr)	2006-10-19

Family

ID=36617258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002598207A Abandoned CA2598207A1 (fr)	2005-04-14	2006-04-13	Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation

Country Status (6)

Country	Link
EP (1)	EP1869013A1 (fr)
JP (1)	JP2008535889A (fr)
CN (1)	CN101160305A (fr)
CA (1)	CA2598207A1 (fr)
DE (1)	DE102005017301A1 (fr)
WO (1)	WO2006108711A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10038639A1 (de) *	2000-07-28	2002-02-21	Schering Ag	Nichtsteroidale Entzündungshemmer
DE10215316C1 (de) *	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
EP1583745A1 (fr) *	2003-01-03	2005-10-12	Boehringer Ingelheim Pharmaceuticals Inc.	Dérivés de 1-propanol et 1-propylamine et leur utilisation en tant que ligands de glucocorticoide
GB0418045D0 (en) *	2004-08-12	2004-09-15	Glaxo Group Ltd	Compounds

2005
- 2005-04-14 DE DE102005017301A patent/DE102005017301A1/de not_active Withdrawn
2006
- 2006-04-13 CN CNA2006800121531A patent/CN101160305A/zh active Pending
- 2006-04-13 WO PCT/EP2006/003780 patent/WO2006108711A1/fr not_active Ceased
- 2006-04-13 JP JP2008505845A patent/JP2008535889A/ja active Pending
- 2006-04-13 CA CA002598207A patent/CA2598207A1/fr not_active Abandoned
- 2006-04-13 EP EP06742670A patent/EP1869013A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
CN101160305A (zh)	2008-04-09
WO2006108711A1 (fr)	2006-10-19
JP2008535889A (ja)	2008-09-04
EP1869013A1 (fr)	2007-12-26
DE102005017301A1 (de)	2006-10-19

Publication	Publication Date	Title
KR100967277B1 (ko)	2010-07-01	퀴놀린 및 이소퀴놀린 유도체, 그의 제조 방법 및항염증제로서의 그의 용도
CA2657006C (fr)	2015-06-16	Benzyl amines, procede pour leur preparation et leur utilisation en tant qu'agents anti-inflammatoires
US7417056B2 (en)	2008-08-26	5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
CN101124220B (zh)	2012-04-25	5-取代的喹啉和异喹啉衍生物、其制备方法及其作为抗炎药的用途
US7880042B2 (en)	2011-02-01	Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics
CA2586973A1 (fr)	2006-06-29	Amino-alcools tricycliques, processus de synthese et utilisation comme anti-inflammatoires
US20070129359A1 (en)	2007-06-07	Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents
US20080188666A1 (en)	2008-08-07	Linear phenyl-substituted indazoles and indoles, a process for their production and their use as anti-inflammatory agents
ES2301056T3 (es)	2008-06-16	Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como agentes antiinflamatorios.
US20070015750A1 (en)	2007-01-18	Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060167025A1 (en)	2006-07-27	Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
US20070015761A1 (en)	2007-01-18	Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060084652A1 (en)	2006-04-20	Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CA2598207A1 (fr)	2006-10-19	Derives de chromane substitues, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation
US20070129358A1 (en)	2007-06-07	Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents
WO2010009814A1 (fr)	2010-01-28	5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl) amino]-1-arylquinoline-2-ones, leur procédé de production et leur utilisation comme agents anti-inflammatoires
CA2598208A1 (fr)	2006-10-19	Derives de tetrahydronaphthaline, procede pour les preparer, et leur utilisation en tant qu'inhibiteurs d'inflammation
WO2008055709A1 (fr)	2008-05-15	Dérivés indoles et indazoles en tant qu'agents anti-inflammatoires
US20080227820A1 (en)	2008-09-18	Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents
EP1921068A1 (fr)	2008-05-14	Dérivés d'indazole et d'indole comme agents anti-inflammatoires

Legal Events

Date	Code	Title	Description
2010-04-13	FZDE	Dead